Table 2.
Clinical and laboratory findings of acute Q fever patients
| Symptoms and laboratory findings | |
|---|---|
| Symptoms | |
| Fever, n (%) | 48 (100) |
| Myalgia, n (%) | 44 (91.7) |
| Headache, n (%) | 30 (62.5) |
| Cough, n (%) | 11 (22.9) |
| Joint pain, n (%) | 7 (14.6) |
| Rash, n (%) | 5 (10.4) |
| Pneumonia, n (%) | 5 (10.4) |
| Elevated transaminases (> 3-fold higher than the upper normal limits), n (%) | 11 (22.9) |
| Autoantibody tests performed, n (%) | 24 (50.0) |
| Tested positive for autoantibodies, n (%) | 16 (66.6%) |
| Initial laboratory test results | |
| White blood cell count (/μl), median (IQR) | 5.98 (4.99–9.27) |
| Leukopenia (< 4000/μl), n (%) | 2 (4.1) |
| Leukocytosis (> 10,000/μl), n (%) | 10 (20.8) |
| Platelet count (× 1000/μl), median (IQR) | 169.0 (133.0–247.5) |
| Thrombocytopenia (< 140,000/μl), n (%) | 15 (31.2) |
| CRP (mg/dL), median (IQR) | 7.7 (5.2–11.2) |
| AST (IU/L), median (IQR) | 72.0 (50.0–98.7) |
| ALT (IU/L), median (IQR) | 76.5 (53.2–97.5) |
| Elevated ALT (> 40 IU/L), n (%) | 41 (85.4) |
| Elevated transaminases (> 3-fold higher than the upper normal limits), n (%) | 11 (22.9) |
| Bilirubin (mg/dL), median (IQR) | 0.65 (0.47–0.95) |
| Interval between illness onset and seeking of medical care, days, median (IQR) | 6.5 (4.0–14.0) |
| Hospitalization, n (%) | 43 (89.6) |
| Length of hospital stay, days, median (IQR) | 6.5 (3.0–10.0) |
| Time to defervescence, days, median (IQR) | 10.0 (7.0–22.8) |
| Time to serologic diagnosis, days, median (IQR) | 21.0 (15.0–40.0) |